Sequential enfortumab vedotin (EV) after platinum-based chemotherapy in metastatic or locally advanced urothelial cancer: Complete response, bladder preservation and survival.

被引：0
|
作者：
Cen, Putao
Chan, Kok Hoe
Canfield, Steven
Shu, Tung
Maithel, Neha
Tammisetti, Varaha
机构：
[1] Univ Texas Hlth Sci Ctr Houston UTHealth Houston, McGovern Med Sch, Houston, TX USA
[2] Univ Texas Med Sch Houston, Houston, TX USA
[3] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
529
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
    Hoimes, Christopher J.
    Rosenberg, Jonathan E.
    Petrylak, Daniel Peter
    Carret, Anne-Sophie
    Melhem-Bertrandt, Amal
    Flaig, Thomas W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] The EV-103 Trial: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for patients with locally advanced or metastatic urothelial
    Hoimes, Christopher J.
    Rosenberg, Jonathan E.
    Petrylak, Daniel P.
    Carret, Anne-Sophie
    Melhem-Bertrandt, Amal
    Flaig, Thomas W.
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 43 - 43
  • [3] EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
    Petrylak, Daniel Peter
    Balar, Arjun Vasant
    O'Donnell, Peter H.
    McGregor, Bradley Alexander
    Heath, Elisabeth I.
    Yu, Evan Y.
    Galsky, Matt D.
    Hahn, Noah M.
    Gartner, Elaina M.
    Pinelli, Juan
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [4] Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
    Mikami, H.
    Endo, Y.
    Akatsuka, J.
    Kimura, G.
    Takeda, H.
    Ikuma, S.
    Taniuchi, M.
    Hasegawa, H.
    Toyama, Y.
    Shibasaki, M.
    Kondo, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1566 - S1566
  • [5] EV-301: Phase Ill study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (Ia/mUC).
    Petrylak, Daniel Peter
    Rosenberg, Jonathan E.
    Duran, Ignacio
    Loriot, Yohann
    Sonpavde, Guru
    Wu, Chunzhang
    Gartner, Elaina M.
    Melhem-Bertrandt, Amal
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Real world outcomes for maintenance avelumab treatment in locally advanced/metastatic urothelial cancer after platinum-based chemotherapy.
    Rehan, Ahmed
    Qureshi, Muneeb
    Aydin, Sabin Goktas
    O'Connor, Kate
    Serra, Maria
    Charnley, Natalie
    Spurgeon, Laura
    Muazzam, Iqtedar
    Bansal, Vikram
    Vasudev, Naveen
    Coe, Faye
    Kagzi, Mohammed Mubashir
    Din, Omar
    Leach, Diane
    Hubbard, Rachel
    Catto, James W. F.
    Hussain, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [7] REAL-WORLD RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
    Kim, Sandra
    Ma, Josh
    Eigl, Bernie
    Alimohamed, Nimira
    Kulkarni, Girish
    Chung, Peter
    Graham, Jeffrey
    Breau, Rodney
    Ong, Michael
    Levesque, Eric
    Basappa, Naveen
    Rendon, Ricardo
    Castilloux, Jean
    Winquist, Eric
    Siemens, Robert
    Lattouf, Jean-Baptiste
    Mukherjee, Som
    Yokom, Daniel
    Kassouf, Wassim
    Black, Peter
    JOURNAL OF UROLOGY, 2024, 211 (05): : E863 - E863
  • [8] EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
    Petrylak, D. P.
    Rosenberg, J. E.
    Lee, J.
    Yonese, J.
    Duran, I.
    Loriot, Y.
    Sonpavde, G.
    Wu, C.
    Gartner, E. M.
    Melhem-Bertrandt, A.
    Powles, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Real-world use, dose intensity, and adherence to enfortumab vedotin (EV) in locally advanced or metastatic urothelial cancer (la/mUC)
    Tsingas, Konstantinos
    Parikh, Ravi Bharat
    Elsouda, Dina
    Mucha, Lisa
    Fuldeore, Rupali
    Hubbard, Rebecca A.
    Mamtani, Ronac
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Pembrolizumab after platinum-based chemotherapy for treatment of metastatic bladder cancer
    Richters, A.
    Van der Heijden, A. G.
    Mehra, N.
    Meijer, R. P.
    Kiemeney, L. A.
    Boormans, J. L.
    Aben, K.
    EUROPEAN UROLOGY, 2024, 85 : S1728 - S1728
12345